Are you Dr. Lenzi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 42 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Summary
- Dr. Renato Lenzi, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Mississippi, and Louisiana. He is affiliated with University of Texas M.D. Anderson Cancer Center and is an Associate Professor of Medicine at University Tex Houston.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1989 - 1990
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1983 - 1986
One Brooklyn Health System/Interfaith Medical CenterResidency, Internal Medicine, 1980 - 1983
University of Cattolica del Sacro CuoreClass of 1977
Certifications & Licensure
NJ State Medical License 1986 - Present
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2025
MS State Medical License 2023 - 2024
LA State Medical License 2023 - 2024
TX State Medical License 1990 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- Join now to see all
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Fellow (FACP) American College of Physicians, 1999
Clinical Trials
- Interleukin-12 in Treating Patients With Cancer in the Abdomen Start of enrollment: 1997 Aug 01
- Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer Start of enrollment: 2001 Jul 01
- Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors Start of enrollment: 2005 Nov 01
Publications & Presentations
PubMed
- 62 citationsEstrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular CarcinomaManal Hassan, Gehan Botrus, Reham Abdel-Wahab, Robert A. Wolff, Donghui Li, David J. Tweardy, Alexandria T. Phan, Ernest T. Hawk, Milind Javle, Ju Seog Lee, Harrys A. ...> ;Clinical Gastroenterology and Hepatology. 2017 Nov 1
- 19 citationsOccult primary, version 3.2014; Featured updates to the NCCN guidelinesDavid S. Ettinger, Charles R. Handorf, Mark Agulnik, Daniel W. Bowles, Justin M M Cates, Mihaela C. Cristea, Efrat Dotan, Keith D. Eaton, Panagiotis Fidias, David S. G...> ;Journal of the National Comprehensive Cancer Network. 2014 Jul 1
- 11 citationsVoice analysis during bad news discussion in oncology: reduced pitch, decreased speaking rate, and nonverbal communication of empathyMonica A. McHenry, Patricia A. Parker, Walter F. Baile, Renato Lenzi> ;Supportive Care in Cancer. 2012 May 1
- Join now to see all
Grant Support
- IP Recombinant IL-12 In Patients With Ovarian Cancer: Phase IINational Center For Research Resources2005
- IP Recombinant IL-12 In Patients With Ovarian CancerNational Center For Research Resources2004
- IP Recombinant Human IL-12 In Patients With Peritoneal CarcinomatosisNational Center For Research Resources1998–2002
- Laboratory Studies With Intraperitoneal Rhil-12 TherapyNational Cancer Institute1998
Professional Memberships
- Fellow
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
